<SEC-DOCUMENT>0000886163-20-000056.txt : 20200506
<SEC-HEADER>0000886163-20-000056.hdr.sgml : 20200506
<ACCEPTANCE-DATETIME>20200506160313
ACCESSION NUMBER:		0000886163-20-000056
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20200506
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20200506
DATE AS OF CHANGE:		20200506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			LIGAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0000886163
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				770160744
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33093
		FILM NUMBER:		20852545

	BUSINESS ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		858-550-7500

	MAIL ADDRESS:	
		STREET 1:		3911 SORRENTO VALLEY BLVD
		STREET 2:		SUITE 110
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>lgnd-20200506.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2020 Workiva--><!--r:68b0d68d-acb4-44fa-8fb0-389d70f74060,g:d3c0284d-4aea-42ef-aa86-73b1c056cdd7,d:8e0647f4ec74488880c2a7c85ddbeb14--><html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>lgnd-20200506</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF80L2ZyYWc6MzExNDFmZDU5MWY1NDQ2NmEyYWM3ODYzMTRiM2Y3NjEvdGFibGU6ZjczMWZhNDRmNzRiNDk2NTg4MTg5OGVlODE0NTA4M2UvdGFibGVyYW5nZTpmNzMxZmE0NGY3NGI0OTY1ODgxODk4ZWU4MTQ1MDgzZV8yLTEtMS0xLTA_7df9b12c-7d3b-44f6-9502-4772b81fb58e">0000886163</ix:nonNumeric><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF80L2ZyYWc6MzExNDFmZDU5MWY1NDQ2NmEyYWM3ODYzMTRiM2Y3NjEvdGFibGU6ZjczMWZhNDRmNzRiNDk2NTg4MTg5OGVlODE0NTA4M2UvdGFibGVyYW5nZTpmNzMxZmE0NGY3NGI0OTY1ODgxODk4ZWU4MTQ1MDgzZV8zLTEtMS0xLTA_649ca818-bc64-410f-b168-55bed80d4d84">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="lgnd-20200506.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000886163</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-06</xbrli:startDate><xbrli:endDate>2020-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i8e0647f4ec74488880c2a7c85ddbeb14_1"></div><div style="height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%;">UNITED STATES</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%;">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:173%;">WASHINGTON, D.C. 20549</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%;">______________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%;">FORM <ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV85Nw_7640994b-b3f2-48a2-963e-64b87c25278d">8-K</ix:nonNumeric> </span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10.5pt;font-weight:700;line-height:173%;">______________</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%;">CURRENT REPORT</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%;">Pursuant to Section 13 or 15(d) of the</span></div><div style="text-align:center;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:173%;">Securities Exchange Act of 1934</span></div><div style="text-align:center;margin-top:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8yNTI_8d4d1570-b7f5-4e47-bc6d-4007a1dec0f2">May 6, 2020</ix:nonNumeric> </span></div><div style="text-align:center;margin-top:12pt;margin-bottom:7pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:173%;"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8yNTY_994597b9-893c-4867-b162-60d626854bad">LIGAND PHARMACEUTICALS INC</ix:nonNumeric>ORPORATED</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">     </span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:86.538%;"><tr><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.333%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:31.334%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6MmRiNDk2Y2VjMWM0NDNlYWIwZDhhODMxNzQ0NGZkMDYvdGFibGVyYW5nZToyZGI0OTZjZWMxYzQ0M2VhYjBkOGE4MzE3NDQ0ZmQwNl8wLTAtMS0xLTA_57e4f534-e176-4dea-b07b-0818f49a2d70">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6MmRiNDk2Y2VjMWM0NDNlYWIwZDhhODMxNzQ0NGZkMDYvdGFibGVyYW5nZToyZGI0OTZjZWMxYzQ0M2VhYjBkOGE4MzE3NDQ0ZmQwNl8wLTEtMS0xLTA_f3990a00-5638-4bcc-9a6a-a9d3b5fdf5d4">001-33093</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6MmRiNDk2Y2VjMWM0NDNlYWIwZDhhODMxNzQ0NGZkMDYvdGFibGVyYW5nZToyZGI0OTZjZWMxYzQ0M2VhYjBkOGE4MzE3NDQ0ZmQwNl8wLTItMS0xLTA_9f00277d-0a79-4f57-9f73-f044e3bd14f1">77-0160744</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(State or other jurisdiction of</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Commission File Number)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(I.R.S. Employer</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">incorporation or organization)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Identification No.)</span></td></tr></table></div><div style="text-align:center;margin-top:3pt;margin-bottom:7pt;"><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:46.717%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:2.203%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:46.880%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8wLTAtMS0xLTA_133912ed-e2e6-44f9-aa55-d520acea1de6">3911 Sorrento Valley Boulevard, Suite 110</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8xLTAtMS0xLTA_b67a6e6a-2c07-4bbf-86e8-85bbacf46776">San Diego</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8yLTAtMS0xLTA_56779583-f645-43be-b9b0-5572cbb990c7">CA</ix:nonNumeric></span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8yLTItMS0xLTA_3bddcea9-9306-4eea-9649-249c4301bfcd">92121</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Address of principal executive offices)</span></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:middle;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:8pt;font-weight:700;font-style:italic;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(Zip Code)</span></td></tr></table></div><div style="text-align:center;margin-top:15pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">(<ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8zMzQ_66d57574-1677-4881-a987-1616dc6b531c">858</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8zMzg_0156b96d-bd43-4845-a696-f535e8f77927">550-7500</ix:nonNumeric> </span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">(Registrant&#8217;s Telephone Number, Including Area Code)</span></div><div style="text-align:center;margin-bottom:3pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:173%;">N/A</span></div><div style="text-align:center;margin-bottom:6pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">(Former Name or Former Address, if Changed Since Last Report)</span></div><div style="text-align:center;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:173%;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</span></div><div><span><br/></span></div><div style="text-indent:-22.5pt;padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%;"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV82MzU_a0e562e0-816f-459f-9cbb-8ee09fcf2a25">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">&#160;Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div style="text-indent:-22.5pt;padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%;"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV83MjQ_404c6f2a-c053-4751-8b38-5b56adc7b922">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">&#160;Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div style="text-indent:-22.5pt;padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%;"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV84MTQ_7cb8f7cc-af9e-49dd-b12d-28915b387667">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">&#160;Pre-commencement communications pursuant to Rule&#160;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div style="text-indent:-22.5pt;padding-left:24.75pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:144%;"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV85MjA_48384577-b3a8-4465-b415-f3eb0ea56eda">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">&#160;Pre-commencement communications pursuant to Rule&#160;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span><br/></span></div></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Securities registered pursuant to Section 12(b) of the Ac</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">t:</span></div><div><span><br/></span></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:98.878%;"><tr><td style="width:1.0%;"></td><td style="width:36.897%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:19.393%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:37.710%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Title of each class</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Trading Symbol(s)</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2I3MTRhYTc3ZDNjNDE2NDlkZWE3YzE5NThmMTg3N2IvdGFibGVyYW5nZTo3YjcxNGFhNzdkM2M0MTY0OWRlYTdjMTk1OGYxODc3Yl8xLTAtMS0xLTA_bb6cecbf-0423-48b8-87be-fb2f6209d5bb">Common Stock, par value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2I3MTRhYTc3ZDNjNDE2NDlkZWE3YzE5NThmMTg3N2IvdGFibGVyYW5nZTo3YjcxNGFhNzdkM2M0MTY0OWRlYTdjMTk1OGYxODc3Yl8xLTEtMS0xLTA_39bf7059-858c-4532-905f-1bb86cd75b66">LGND</ix:nonNumeric></span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:1pt solid #000000;border-left:1pt solid #000000;padding-left:1pt;border-right:1pt solid #000000;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2I3MTRhYTc3ZDNjNDE2NDlkZWE3YzE5NThmMTg3N2IvdGFibGVyYW5nZTo3YjcxNGFhNzdkM2M0MTY0OWRlYTdjMTk1OGYxODc3Yl8xLTItMS0xLTA_1438e758-265a-477f-8782-bb8b5f0dbd66">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="text-indent:-22.5pt;padding-left:24.75pt;"><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Emerging growth company  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;"><ix:nonNumeric contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8xMzU0_766ad7f2-584f-4ba2-a079-1756ff76b9c6">&#9744;</ix:nonNumeric></span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div><span><br/></span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#9744;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">&#160;</span></div><div><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> </span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><div id="i8e0647f4ec74488880c2a7c85ddbeb14_7"></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span><br/></span></div></div><div style="margin-bottom:12pt;-sec-extract:summary;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">Item 2.02 Results of Operations and Financial Condition.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">On May 6, 2020, Ligand Pharmaceuticals Incorporated (the &#8220;Company&#8221;) issued a press release announcing its financial results for the three months ended March 31, 2020. A copy of this press release is furnished herewith as Exhibit 99.1 to this report.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:144%;">In accordance with General Instruction B.2. of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.</span></div><div style="text-align:justify;margin-bottom:12pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:144%;">Item 9.01 Financial Statements and Exhibits.</span></div><div style="margin-bottom:19pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;">(d)&#160;Exhibits.</span></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:100.000%;"><tr><td style="width:1.0%;"></td><td style="width:12.150%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:83.850%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:3pt;text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Exhibit No.</span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="padding-right:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;">Description</span></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-right:3pt;text-align:center;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;"><a style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;-sec-extract:exhibit;" href="q12020earningsreleasee.htm">99.1</a></span></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"><div style="padding-left:3pt;padding-right:-3pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Press release dated May 6, 2020.</span></div></td></tr></table></div><div style="margin-top:3pt;margin-bottom:12pt;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div><span><br/></span></div><div style="text-align:justify;"><span><br/></span></div><div style="margin-top:6pt;"><span><br/></span></div><div style="margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="height:72pt;width:100%;"><div><span><br/></span></div></div><div style="text-align:center;margin-bottom:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">SIGNATURES</span></div><div style="text-indent:36pt;text-align:justify;margin-bottom:20pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span></div><div style="padding-left:18pt;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.993%;"><tr><td style="width:1.0%;"></td><td style="width:40.070%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:55.930%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">LIGAND PHARMACEUTICALS INCORPORATED</span></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:2.25pt;padding-right:1pt;"><span style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Date: May 6, 2020</span></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:top;padding-left:1pt;padding-right:1pt;"><div style="text-indent:-33.75pt;padding-left:38.25pt;padding-right:2.25pt;margin-top:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">By:   </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration: underline;">/s/ Charles S. Berkman         </span></div><div style="text-indent:-33.75pt;padding-left:38.25pt;padding-right:2.25pt;margin-top:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Name:    Charles S. Berkman</span></div><div style="text-indent:-33.75pt;padding-left:38.25pt;padding-right:2.25pt;margin-top:2pt;margin-bottom:2pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;">Title:    Senior Vice President, General Counsel and Secretary </span></div></td></tr></table></div><div style="margin-top:9pt;"><span><br/></span></div><div style="text-indent:36pt;margin-bottom:12pt;"><span><br/></span></div><div style="position:relative;width:100%;height:72pt;"><div style="position:absolute;bottom:0;width:100%;"><div><span><br/></span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>q12020earningsreleasee.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2020 Workiva -->
<title>Document</title></head><body><div id="i62a27f6a7e2842e18b4ec12f0092b46a_1"></div><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-indent:18pt;"><font><br></font></div><div style="text-indent:18pt;"><font><br></font></div><div><img alt="image11.jpg" src="image11.jpg" style="height:69px;width:196px;"></div><div style="margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:97.660%;"><tr><td style="width:1.0%;"></td><td style="width:6.532%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:29.886%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.898%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:6.383%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:23.301%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:100%;">Contacts&#58;</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Ligand Pharmaceuticals Incorporated</font></div></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">LHA Investor Relations</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Patrick O'Brien</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="6" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Bruce Voss</font></div></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Email&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;">investors&#64;ligand.com</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Email&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;text-decoration: underline;">bvoss&#64;lhai.com</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Phone&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:11pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(858) 550-7893</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Phone&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">(310) 691-7100</font></div></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">Twitter&#58;</font></div></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%;">&#64;Ligand_LGND</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Ligand Reports First Quarter 2020 Financial Results</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Raises 2020 Financial Guidance</font></div><div><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%;">Conference Call with Slides Begins at 4&#58;30 p.m. Eastern Time Today</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">SAN DIEGO (May 6, 2020) &#8211; Ligand Pharmaceuticals Incorporated (NASDAQ&#58; LGND)</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;"> today reported financial results for the three months ended March 31, 2020 and provided an operating forecast and program updates.  Ligand management will host a conference call with slides today beginning at 4&#58;30 p.m. Eastern time to discuss this announcement and answer questions. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8220;Our first quarter financial results feature strong sales of Captisol to partners evaluating remdesivir in multiple clinical trials and scaling-up for potential treatment courses for COVID-19.  We continue to meet Captisol requirements to support these trials as well as manufacturing scale-up, and are proud to play a role in developing potential treatments to address the pandemic both with Captisol and with various OmniAb</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174; </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">and Vernalis-derived product candidates,&#8221; said John Higgins, Chief Executive Officer of Ligand.  &#8220;We recently closed a strategic acquisition, and throughout the first quarter we added a number of Shots on Goal with new agreements for various technologies, in particular our OmniAb platform.  Overall, our business is performing very well, especially given the difficult business environment due to the pandemic.  As such, we are pleased to be raising our 2020 financial guidance.&#8221;</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">COVID-19 Impact</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">As the COVID-19 pandemic continues to evolve, our primary concern remains the health and safety of our employees and partners globally, while we continue to take actions to help address the pandemic. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">We are supporting our employees through a range of programs, have enabled working from home and staggered operations in our labs and other critical work spaces.  Importantly, Ligand is committed that there will be no COVID-19 related layoffs.  Our corporate structure is spread across five sites in the U.S. and England, which positions us well to operate effectively in the current remote working environment.  The Ligand team is ready to support a return to full operations with appropriate social distancing measures in place, following the lifting of shelter-in-place restrictions. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">We have a very strong balance sheet, and we anticipate no material operational impacts for the rest of the year due to COVID-19.  During the first quarter, COVID-19 did not have a material negative impact on our underlying business, financial condition, cash collections or liquidity.  During the first quarter we reduced our outstanding convertible debt by approximately one-third given the favorable pricing on the bonds and the lower interest rate environment.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Our partnership with Gilead Sciences for remdesivir resulted in an increase in sales of Captisol to supply the scale up and manufacturing of that medicine as the first new treatment for COVID-19 available under an Emergency Use Authorization.  We do not anticipate supply chain disruption for Captisol production at this time given inventory levels, risk management measures and operations at multiple sites throughout the world.  We believe we are well positioned to meet Captisol requirements and are planning to make further capital investments in plant and operational capacity.  </font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">We have a large portfolio of more than 200 programs fully funded by more than 125 different pharmaceutical and biotechnology companies.  We recently surveyed all our partners and found that the majority of them are generally in a relatively strong capital and operating condition with limited expected long-term impact on our partnered programs.  Looking ahead to the remainder of the year and after thoroughly analyzing our business, we anticipate royalty and contract revenue will be lower than originally forecasted.  We believe that patient access to certain medicines around the world will be disrupted over several months, which may decrease revenue for products from which we earn royalties.  In addition, we anticipate that some partners will delay trial initiations or experience a slowdown in patient enrollment.  These delays and slowdowns will likely reduce milestone payments for contract revenue due to Ligand.  In addition, some smaller partners may face cash constraints or difficulty raising new capital, which could impact their ability to make payments to Ligand.  Nonetheless, as the economy begins to reopen we expect our partners will resume important clinical and regulatory work on a wide array of partnered programs.  Additionally, to date the increase in sales of Captisol has more than offset our projected decline in royalty and contract revenues.  While the mix of revenue will be different than our original outlook, we anticipate total revenue and earnings to be higher in 2020 compared to our previous guidance. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Ligand has multiple programs relating to potential treatments for COVID-19.  One is with Gilead for remdesivir, a nucleotide analogue issued an Emergency Use Authorization by the U.S. Food and Drug Administration on May 1, 2020.  We also have two OmniAb partners with antibody programs in discovery stage, and a heat shock protein program that was added to our R&#38;D programs when we acquired Vernalis.  </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">First Quarter 2020 Financial Results</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Total revenues for the first quarter of 2020 were $33.2 million, compared with $43.5 million for the same period in 2019.  Royalties for the first quarter of 2020 were $6.6 million and primarily consisted of royalties from Kyprolis</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;"> and EVOMELA</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">.  Royalties for the first quarter of 2019 were $19.5 million and included $14.2 million in royalties from Promacta&#59; Ligand sold its Promacta license to Royalty Pharma as of March 6, 2019.  Captisol sales were $21.1 million for the first quarter of 2020, compared with $9.0 million for the same period in 2019, primarily reflecting higher sales of Captisol for remdesivir.  Effective this quarter, Ligand is presenting service revenue as a separate line item. Service revenue includes revenue generated from our Vernalis, Icagen and OmniChicken businesses as we collaborate with partners on early stage discovery and development work, and was $3.4 million for the first quarter of 2020, compared with $3.9 million for the same period in 2019.  Contract revenue was $2.1 million for the first quarter of 2020, compared with $11.1 million for the same period in 2019, with the change driven by the timing of partner events.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Cost of Captisol was $4.7 million for the first quarter of 2020, compared with $3.9 million for the same period in 2019.  Amortization of intangibles was $3.5 million for the first quarter of both 2020 and 2019.  Research and development expense was $11.9 million for the first quarter of 2020, compared with $11.3 million for the same period of 2019.  General and administrative expense was $9.3 million for the first quarter of 2020, compared with $11.1 million for the same period in 2019, with the decrease primarily attributable to lower legal expenses. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Net loss for the first quarter of 2020 was $(24.1) million, or $(1.46) per diluted share, compared with net income of $666.3 million, or $31.32 per diluted share, for the same period in 2019.  The net loss for the first quarter of 2020 includes a non-cash change in the value of Ligand&#8217;s investments of $(25.5) million, while net income for the first quarter of 2019 includes a $17.3 million net non-cash gain from the value of Ligand&#8217;s investments as well as a $640.3 million gain, net of taxes, from the sale of the Promacta license.  Adjusted net income for the first quarter of 2020 was $15.3 million, or $0.89 per diluted share, compared with $24.7 million, or $1.16 per diluted share, for the same period in 2019.  Please see the table below for a reconciliation of net income&#47;(loss) to adjusted net income.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">As of March 31, 2020, Ligand had cash, cash equivalents and short-term investments of $738.8 million.  During the first quarter of 2020, Ligand repurchased $234 million in principal amount of its convertibles notes at a price of $203 million, and repurchased 878,525 common shares for $73.3 million. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">2020 Financial Guidance</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Ligand is raising its 2020 financial guidance.  Ligand now expects 2020 total revenues to be approximately $140 million and diluted EPS to be $3.65, up from previous guidance for total revenues of approximately $133 million and diluted EPS of $3.62.  This increase reflects Ligand&#8217;s revised view on the business incorporating an estimated impact from COVID-19.  The revised estimate of approximately $140 million in total revenues includes higher sales of Captisol, partially offset by reductions in royalties and contract revenue.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">First Quarter 2020 and Recent Business Highlights </font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">Kyprolis</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:top;">&#174; </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">(carfilzomib), an Amgen Product Utilizing Captisol</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Amgen reported first quarter Kyprolis</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;"> sales of $280 million.  Ono Pharmaceutical Co. will report first quarter Kyprolis sales in Japan on May 11, 2020.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">OmniAb</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;"> Platform Updates</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">There are now more than 80 OmniAb-related Shots on Goal in Ligand&#8217;s partnered portfolio, representing over 40% of the Ligand pipeline. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">OmniAb partners have filed or been issued more than 30 U.S. and international patent applications or patents, claiming OmniAb-derived antibodies as the primary invention.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">The number of active or recently completed clinical trials that include an OmniAb-derived antibody reached 43, with new clinical trial starts in Q1 that included&#58;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#9702;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.11pt;">two new Phase 1&#47;1b trials&#59;</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#9702;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.11pt;">three new Phase 2 trials&#59; and</font></div><div style="text-indent:-18pt;padding-left:72pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#9702;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.11pt;">two new Phase 3 trials.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Two COVID-19 antibody programs are being pursued by Ligand partners.  One is a multinational Big Pharma partner that has initiated a program using OmniChicken</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">, and the other is focused on antibodies derived from OmniRat</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Immunovant announced positive results from its Phase 2a proof-of-concept study of OmniAb-derived IMVT-1401 in thyroid eye disease. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">IMVT-1401 is a novel investigational anti-FcRn antibody delivered by subcutaneous injection. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;"> </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">The results showed a 65% mean reduction in total IgG observed from baseline to end of treatment, with a pharmacodynamic response nearly identical to modeled predictions for the dosing regimen tested in the trial. IMVT-1401 was generally well-tolerated.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Janssen initiated a </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Phase 1b trial of OmniAb-derived teclistamab (also known as JNJ-64007957) in combination with subcutaneous daratumumab in patients with multiple myeloma to identify a Phase 2 dose regimen and assess safety of the combination</font><font style="background-color:#ffffff;color:#444444;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">.  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Gloria Biosciences submitted an application for marketing approval in China for OmniAb-derived zimberelimab for the treatment of classical Hodgkin lymphoma, marking multiple OmniAb drug applications filed seeking approval.  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Arcus Biosciences and Taiho Pharmaceutical announced Taiho&#8217;s exercise of its option for an exclusive license to zimberelimab (also known as AB122) for Japan and other Asian countries, excluding China.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Ligand entered into an OmniAb Platform agreement with Pandion Therapeutics, and Pandion subsequently closed an $80 million financing and announced that proceeds will support the advancement of their pipeline of modular proteins and bi-functional antibodies for the treatment of autoimmune diseases. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">CStone Pharmaceuticals and Blueprint Medicines initiated a Phase 1b&#47;2 clinical trial of fisogatinib in combination with OmniAb-derived CS1001 for patients with hepatocellular carcinoma.  CStone also announced that the first patient was dosed in the global proof-of-concept study of OmniAb-derived CS1001 in combination with Bayer's regorafenib in patients with advanced solid tumors. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Harbour BioMed raised $75 million to fund the clinical development of an OmniAb-derived anti-FcRn antibody batoclimab, among other uses.  Harbour also announced first patient dosing of Phase 1b&#47;2a study of batoclimab for treating neuromyelitis optica spectrum disorder.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">OmniAb partner GenMab highlighted DuoBody-PD-L1x4-1BB (GEN1046) at the J.P. Morgan investor conference in January&#59; the GEN1046 anti-PD-L1 is derived from OmniRat.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">Captisol</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.8pt;font-style:italic;font-weight:700;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;"> Business Update </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Ligand&#8217;s Captisol is a patented ultra-high pure form of sulfobutylether beta-cyclodextrin (SBECD) that is built upon drug master files maintained in multiple countries and has an extensive safety record for use in intravenous, inhaled, subcutaneous, oral, and ophthalmic formulations, among others.  Ligand is the sole supplier of Captisol globally.    </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Ligand announced that it is supplying Captisol to partners for remdesivir in clinical trials and for manufacturing scale-up as a treatment for COVID-19.  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">On May 1, 2020 remdesivir was the first new treatment for COVID-19 to be issued an Emergency Use Authorization. Gilead announced that it intends to donate 1.5 million doses of remdesivir.  Gilead has also stated that it is expanding manufacturing to increase product supply to over 1 million treatment courses by December 2020 ahead of potential increased demand. </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">On April 29, 2020 Gilead announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease.  The study demonstrated that patients receiving a 5-day treatment course of remdesivir achieved similar improvement in clinical status compared with those taking a 10-day treatment course.  The study demonstrated the potential for some patients to be treated with a 5-day regimen, which could significantly expand the number of patients who could be treated with Gilead&#8217;s current supply of remdesivir.  The study results complement positive data from a placebo-controlled Phase 3 study of remdesivir conducted by the National Institute for Allergy and Infectious Diseases also reported on April 29, 2020, and may help to determine the optimal duration of treatment with remdesivir.   </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Ligand&#8217;s Captisol network is served by manufacturing plants in two European countries and five distribution facilities around the globe, all of which remain fully operational.  Ligand has substantial capacity to supply Captisol manufactured according to cGMP and its focus is to ensure sufficient supply to meet all existing and future partner needs, and to supply Gilead.  Ligand is also evaluating plans with its supply partners to further increase capacity by bringing additional sites online, if needed.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">During the first quarter, Ligand entered into Captisol clinical use agreements with Double-Crane Pharmaceuticals and OnKure Therapeutics.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">Vernalis Business Update</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Ligand entered into an exclusive worldwide license agreement with Neuritek Therapeutics to develop and commercialize V158866, a novel oral, selective fatty acid amide hydrolase inhibitor that was discovered using the Vernalis Design Platform.  Neuritek plans to develop V158866 for post-traumatic stress disorder and other CNS diseases.  Under the terms of the agreement, Ligand will receive an upfront license fee and is eligible to receive over $240 million in milestones and tiered royalties on net sales six to eight percent.  On March 31, 2020 Neuritek announced it had secured approximately $27 million in a capital commitment from GEM Global Yield LLC SCS.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Third-party academic drug analyses suggest a potential role for heat shock protein 90 (Hsp90) inhibitors in treating COVID-19 infection.  Based on these studies, Ligand is evaluating potential collaborations or partnerships relating to intravenous luminespib (AUY-922) as a potential treatment for patients with COVID-19.  Luminespib is a Phase 2-ready Hsp90 inhibitor, previously investigated in clinical trials for cancer.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">Additional Pipeline and Partner Developments</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Retrophin announced that the first 190 patients have been enrolled in its pivotal Phase 3 DUPLEX Study evaluating the safety and efficacy of sparsentan in focal segmental glomerulosclerosis.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Nucorion Pharmaceuticals initiated a Phase 1 clinical trial of NCO-48 Fumarate (NCO-1010), an oral prodrug of the nucleotide tenofovir utilizing Ligand&#8217;s LTP Platform&#8482; technology for the potential treatment of hepatitis B.  The first-in-human, double-blind, placebo-controlled, randomized, ascending single oral dose study will evaluate the safety and tolerability of NCO-48 Fumarate in healthy subjects. Topline results are expected in August 2020.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Palvella Therapeutics announced the completion of enrollment in its seamless Phase 2&#47;3 VALO Study of PTX-022 (QTORIN&#8482; 3.9% rapamycin anhydrous gel) for the treatment of adults with pachyonchia congenita.  </font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Verona Pharma reported positive topline data in its 4-week Phase 2b COPD study with nebulized ensifentrine on top of tiotropium therapy, and also reported positive efficacy and safety data with a single </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">dose of the pressurized metered-dose inhaler (pMDI) formulation of ensifentrine in a Phase 2 COPD study.  Ensifentrine has demonstrated statistically significant and clinically meaningful improvements in lung function in Phase 2 studies in COPD patients when delivered via all three widely used inhaled formulations&#58; nebulizer, DPI and pMDI.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Corvus Pharmaceuticals presented clinical data from its Phase 1b&#47;2 trial of ciforadenant at the 2020 American Society of Clinical Oncology&#8217;s Genitourinary Cancers Symposium.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Ligand regained global rights to its novel glucagon receptor antagonist (formerly known as LGD-6972 and RVT-1502) from Metavant Sciences.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:115%;">Business Development and Corporate Highlights</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Following the close of the first quarter, Ligand completed its acquisition of the core assets of Icagen, Inc.&#8217;s North Carolina operations, including partnered programs, proprietary ion channel screening and assay platforms, x-ray fluorescence capabilities, custom screening technologies and novel unpartnered preclinical-stage molecules for $15 million in cash.</font></div><div style="text-indent:-18pt;padding-left:36pt;text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">&#8226;</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;padding-left:14.15pt;">Ligand announced the launch of its Environmental, Social and Corporate Responsibility Governance section of its corporate website.  Please visit this link for current disclosures. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:95%;">Adjusted Financial Measures</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">The Company reports adjusted net income and adjusted net income per diluted share in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP.  The Company&#8217;s financial measures under GAAP include share-based compensation expense, amortization of debt-related costs, amortization related to acquisitions and intangible assets, changes in contingent liabilities, mark-to-market adjustments for amounts relating to its equity investments in public companies, excess tax benefit from share-based compensation, gain on the sale of Promacta and others that are listed in the itemized reconciliations between GAAP and adjusted financial measures included at the end of this press release.  However, other than with respect to total revenues, the Company only provides financial guidance on an adjusted basis and does not provide reconciliations of such forward-looking adjusted measures to GAAP due to the inherent difficulty in forecasting and quantifying certain amounts that are necessary for such reconciliation, including adjustments that could be made for changes in contingent liabilities, changes in the market value of its investments in public companies, stock-based compensation expense and effects of any discrete income tax items.  Management has excluded the effects of these items in its adjusted measures to assist investors in analyzing and assessing the Company&#8217;s past and future core operating performance.  Additionally, adjusted earnings per diluted share is a key component of the financial metrics utilized by the Company&#8217;s board of directors to measure, in part, management&#8217;s performance and determine significant elements of management&#8217;s compensation.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">Conference Call</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Ligand management will host a conference call with slides today beginning at 4&#58;30 p.m. Eastern time (1&#58;30 p.m. Pacific time) to discuss this announcement and answer questions.  To participate via telephone, please dial (833) 325-0071 from the U.S. or (720) 405-1612 from outside the U.S., using the conference ID 5190682.  To participate via live or replay webcast, a link is available at www.ligand.com. Slides to accompany the conference call are available </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;text-decoration: underline;">here</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">About Ligand Pharmaceuticals</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Ligand is a revenue-generating biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.  Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure.  Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company.  Our business model is based on doing what we do best&#58; drug discovery, early-stage drug development, product reformulation and partnering.  We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue.  Ligand&#8217;s OmniAb&#174; technology platform is a patent-protected transgenic animal platform used in the discovery of fully human mono- and bispecific therapeutic antibodies.  The Captisol platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs.  The Vernalis Design Platform (VDP) integrates protein structure determination and engineering, fragment screening and </font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">molecular modeling, with medicinal chemistry, to help enable success in novel drug discovery programs against highly-challenging targets. Ab Initio&#8482; technology and services for the design and preparation of customized antigens enable the successful discovery of therapeutic antibodies against difficult-to-access cellular targets.  Ligand has established multiple alliances, licenses and other business relationships with the world&#8217;s leading pharmaceutical companies including Amgen, Merck, Pfizer, Sanofi, Janssen, Takeda, Gilead Sciences and Baxter International.  For more information, please visit www.ligand.com. </font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Follow Ligand on Twitter &#64;Ligand_LGND.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">Forward-Looking Statements</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">This news release contains forward-looking statements by Ligand that involve risks and uncertainties and reflect Ligand's judgment as of the date of this release. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Words such as &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; and &#8220;will,&#8221; and similar expressions, are intended to identify forward-looking statements. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">These forward-looking statements include, without limitation, statements regarding&#58; Ligand&#8217;s ability to supply Captisol to Gilead and other partners&#59; the potential opportunities for Ligand and its partners related to development of COVID-19 treatments&#59; the</font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;">  </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">impacts that the COVID-19 pandemic will have on Ligand and its partners&#59; Ligand&#8217;s belief that recent events in its partnered programs will enhance value&#59; whether Ligand&#8217;s pipeline will provide a source of growth and future diversified cash flow&#59; the potential entry into new license or partnering agreements&#59; the timing of the initiation or completion of preclinical studies and clinical trials by Ligand and its partners&#59; the timing of product launches by Ligand or its partners&#59; and guidance regarding the full-year 2020 financial results. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Actual events or results may differ from Ligand's expectations due to risks and uncertainties inherent in Ligand&#8217;s business, including, without limitation&#58; Ligand may not receive expected revenue from royalties, Captisol sales, contract and service revenue&#59; the COVID-19 pandemic has disrupted Ligand&#8217;s and its partners&#8217; business, including delaying manufacturing, pre-clinical studies and clinical trials and product sales, and impairing global economic activity, all of which could materially and adversely impact Ligand&#8217;s results of operations and financial condition&#59; Ligand and its partners may not be able to timely or successfully advance any product(s) in its internal or partnered pipeline&#59; Ligand may not achieve its guidance for 2020&#59; development of product candidates by Ligand partners may not be successful, and may not results in increases in Captisol sales&#59; remdesivir may be later shown to not be effective or safe for the treatment of COVID-19 and&#47;or the FDA may revise or revoke its emergency use authorization for remdesivir for the treatment of COVID-19 in patients hospitalized with severe disease if the FDA determines that authorization no longer meets the statutory criteria for issuance&#59; Ligand may not be able to create future revenues and cash flows by developing innovative therapeutics&#59; results of any clinical study may not be timely, favorable or confirmed by later studies&#59; products under development by Ligand or its partners may not receive regulatory approval&#59; there may not be a market for the product(s) even if successfully developed and approved&#59; Amgen, Acrotech Biopharma, Sage Therapeutics or other Ligand partners, may not execute on their sales and marketing plans for marketed products for which Ligand has an economic interest&#59; Ligand or its partners may not be able to protect their intellectual property and patents covering certain products and technologies may be challenged or invalidated&#59; Ligand's partners may terminate any of its agreements or development or commercialization of any of its products&#59; Ligand may not generate expected revenues under its existing license agreements and may experience significant costs as the result of potential delays under its supply agreements&#59; Ligand and its partners may experience delays in the commencement, enrollment, completion or analysis of clinical testing for its product candidates, or significant issues regarding the adequacy of its clinical trial designs or the execution of its clinical trials, which could result in increased costs and delays, or limit Ligand's ability to obtain regulatory approval&#59; unexpected adverse side effects or inadequate therapeutic efficacy of Ligand's product(s) could delay or prevent regulatory approval or commercialization&#59; Ligand may not be able to successfully implement its strategic growth plan and continue the development of its proprietary programs&#59; and ongoing or future litigation could expose Ligand to significant liabilities and have a material adverse effect on the company. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">The failure to meet expectations with respect to any of the foregoing matters may reduce Ligand's stock price. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Additional information concerning these and other risk factors affecting Ligand can be found in prior press releases available at www.ligand.com as well as in Ligand's public periodic filings with the Securities and Exchange Commission available at www.sec.gov. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Ligand disclaims any intent or obligation to update these forward-looking statements beyond the date of this release, including the possibility of additional contract revenue we may receive. </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:115%;"> </font><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.</font></div><div><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:115%;">Other Disclaimers and Trademarks</font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">The information in this press release regarding certain third-party products and programs, including Kyprolis, an Amgen product, EVOMELA, an Acrotech Biopharma product, and ZULRESSO, a Sage Therapeutics product, comes from information publicly released by the owners of such products and programs.  Ligand is not responsible for, and has no role in, the development of such products or programs.</font></div><div><font><br></font></div><div style="text-align:justify;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">Ligand owns or has rights to trademarks and copyrights that it uses in connection with the operation of its business including its corporate name, logos and websites. Other trademarks and copyrights appearing in this press release are the property of their respective owners.  The trademarks Ligand owns include Ligand</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">, Captisol</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174; </sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">and OmniAb</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:7.15pt;font-weight:400;line-height:115%;vertical-align:top;">&#174;</sup><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:115%;">. Solely for convenience, some of the trademarks and copyrights referred to in this press release are listed without the &#174;, &#169; and &#8482; symbols, but Ligand will assert, to the fullest extent under applicable law, its rights to its trademarks and copyrights.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">&#91;Tables Follow&#93;</font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:174%;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Unaudited, in thousands, except per share amounts)</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:95.467%;"><tr><td style="width:1.0%;"></td><td style="width:67.372%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:12.548%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.331%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.549%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three Months Ended March 31, </font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Revenues&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Royalties</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,565&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,538&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Captisol</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,109&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">8,959&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Service revenue</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,357&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,883&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Contract revenue</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,130&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,104&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-left:24pt;padding-right:-24pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Total revenues</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">33,161&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,484&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;">Operating costs and expenses&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Cost of Captisol</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,683&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,858&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization of intangibles</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,535&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,503&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Research and development</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,891&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,289&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">General and administrative</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">9,264&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,088&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-48pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total operating costs and expenses</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,373&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,738&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from sale of Promacta license</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">812,797&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income from operations</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,788&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">826,543&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain (loss) from Viking</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(25,457)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,293&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Interest expense, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(3,818)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,997)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Other expense, net</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(4,928)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,874&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-72pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total other income (loss), net</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(34,203)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,170&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income (loss) before income taxes</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30,415)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">842,713&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Income tax benefit (expense)</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,284&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(176,376)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)&#58;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,131)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">666,337&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Basic net income (loss) per share</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.46)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32.59&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Shares used in basic per share calculation</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,529&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,447&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:9pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Diluted net income (loss) per share</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.46)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.32&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;">Shares used in diluted per share calculations</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,529&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,277&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:3pt double #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:11pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%;">CONDENSED CONSOLIDATED BALANCE SHEETS</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Unaudited, in thousands)</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:91.812%;"><tr><td style="width:1.0%;"></td><td style="width:58.191%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:17.108%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:1.392%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:17.109%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">December 31, 2019</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">ASSETS</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #333333;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:2pt solid #333333;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Current assets&#58;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-84pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Cash, cash equivalents and short-term investments</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">738,811&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,011,532&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Investment in Viking</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,879&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">58,335&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-96pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Accounts receivable, net</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">39,506&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">30,387&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-120pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Inventory</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,320&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,296&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-132pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Income taxes receivable</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,271&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">11,361&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-144pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Other current assets</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,940&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,734&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-96pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current assets</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">830,727&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,123,645&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Deferred income taxes, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">26,358&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,608&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Goodwill and other identifiable intangible assets, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">300,861&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">305,677&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Commercial license and other economic rights, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">10,381&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,090&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;Other assets</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,590&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">19,895&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-120pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total assets</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,185,917&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,494,915&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">LIABILITIES AND STOCKHOLDERS' EQUITY</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000000;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Current liabilities&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-156pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Accounts payable and accrued liabilities</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,213&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">12,256&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-168pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;Current contingent liabilities</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">871&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,607&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;&#160;&#160;&#160;&#160;&#160;Deferred revenue</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,354&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,139&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-144pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total current liabilities</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">20,438&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,002&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-204pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">2023 convertible senior notes, net</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">444,432&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">638,959&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Long-term contingent liabilities</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,811&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">6,335&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Deferred income taxes, net</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,769&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,937&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other long-term liabilities</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31,571&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">32,450&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-168pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">524,021&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">727,683&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Total stockholders' equity</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">661,896&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">767,232&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div style="padding-right:-192pt;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Total liabilities and stockholders' equity</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,185,917&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,494,915&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;border-bottom:3pt double #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr></table></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ADJUSTED FINANCIAL MEASURES</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Unaudited, in thousands, except per share amounts)</font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:94.736%;"><tr><td style="width:1.0%;"></td><td style="width:67.598%;"></td><td style="width:1.0%;"></td><td style="width:1.0%;"></td><td style="width:13.432%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.571%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:12.199%;"></td><td style="width:1.0%;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="9" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended March 31,</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2020</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;border-top:1pt solid #333333;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2019</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:6pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(24,131)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">666,337&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,653&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">5,347&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Non-cash interest expense</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,203&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">7,449&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization related to acquisitions and intangible assets</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,535&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,503&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Amortization of commercial license and other economic rights</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,730&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">2,437&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Change in contingent liabilities</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(367)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1,388&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Acquisition and integrations costs</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">311&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss (gain) from Viking</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">25,457&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(17,293)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Unrealized (gain) loss in equity securities</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">4,234&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(2,257)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">258&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(854)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Income tax effect of adjusted reconciling items above</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(9,411)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(7)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Excess tax benefit from share-based compensation</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(6)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(886)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1,371)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,275&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">664,990&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from sale of Promacta license, net of tax</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(640,265)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Adjusted net income</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">15,275&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,725&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;">Diluted per-share amounts attributable to common shareholders&#58;</font></div></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #333333;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #333333;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Net income (loss)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(1.46)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.32&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Share-based compensation expense</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.34&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.25&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Non-cash interest expense</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(1)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.44&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.35&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Amortization related to acquisitions and intangible assets</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.21&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.16&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Amortization of commercial license and other economic rights</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(2)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.23&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.11&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Change in contingent liabilities</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(3)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.02)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.07&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Acquisition and integrations costs</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(4)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Loss (gain) from Viking</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.54&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.82)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Unrealized (gain) loss in equity securities</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(5)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.26&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.11)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Other</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.01&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.04)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Income tax effect of adjusted reconciling items above</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.57)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Excess tax benefit from share-based compensation</font><sup style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:100%;vertical-align:top;">(6)</sup></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.05)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.06)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjustment for shares excluded due to anti-dilution effect on GAAP net loss</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(0.04)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.89&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">31.25&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Gain from sale of Promacta license, net of tax</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(30.09)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Adjusted net income</font></div></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.89&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000000;padding-left:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">1.16&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:9pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:3pt double #000;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GAAP - Weighted average number of common shares-diluted</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">16,529&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,277&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add&#58; Shares excluded due to anti-dilutive effect on GAAP net loss</font></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">611&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#8212;&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">Adjusted weighted average number of common shares-diluted</font></div></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">17,140&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-left:1pt;padding-right:0%;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,277&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;border-bottom:3pt double #000;padding-right:1pt;"><font style="font-size:8pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td><td colspan="3" style="display:none;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%;">(1) Amounts represent non-cash debt related costs that are calculated in accordance with the authoritative accounting guidance for convertible debt instruments that may be settled in cash.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(2) For the three months ended March&#160;31, 2020, the amounts represent the amortization of commercial license and other economic rights to revenue and research and development expenses in amounts of $1,222 and $2,508, respectively. For the three months ended March&#160;31, 2019, the amounts represent the amortization of commercial license and other economic rights to revenue and research and development expenses in the amounts of $1,245 and $1,192, respectively.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(3) Amounts represent changes in fair value of contingent consideration related to Crystal, CyDex and Metabasis transactions.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(4) Amounts represent severance costs and certain contract termination costs in connection with the acquisition of Vernalis plc.</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(5) Amounts represent mark to market adjustments associated with our mutual funds and equity investments in Retrophin, Seelos and Nucorion, net of amounts due to a third party licensor.</font></div><div><font><br></font></div><div><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%;">(6) Excess tax benefits from share-based compensation are recorded as a discrete item within the provision for income taxes on the consolidated statement of operations as a result of the adoption of an accounting pronouncement (ASU 2016-09) on January 1, 2017. Prior to the adoption, the amount was recognized in additional paid-in capital on the consolidated statement of stockholders' equity.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="height:45pt;width:100%;"><div><font><br></font></div></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">LIGAND PHARMACEUTICALS INCORPORATED</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;">ADJUSTED FINANCIAL MEASURES</font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%;">(Unaudited, in thousands, except per share amounts)</font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;margin-bottom:6pt;"><table style="margin-left:auto;margin-right:auto;border-collapse:collapse;text-align:left;text-indent:0pt;display:inline-table;width:96.198%;"><tr><td style="width:1.0%;"></td><td style="width:76.267%;"></td><td style="width:1.0%;"></td><td style="width:0.1%;"></td><td style="width:0.863%;"></td><td style="width:0.1%;"></td><td style="width:1.0%;"></td><td style="width:18.670%;"></td><td style="width:1.0%;"></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Three months ended</font></td></tr><tr><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:center;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:700;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">March 31, 2019</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Consolidated revenue</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">43,484&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#58; royalty revenue from Promacta</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,193)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted consolidated revenue</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">29,291&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted net income</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">24,725&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Less&#58; royalty revenue from Promacta</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">(14,193)</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Add&#58; tax effect of the royalty revenue from Promacta</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">3,048&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted net income excluding royalty revenue from Promacta</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;border-top:1pt solid #000;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">13,580&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;border-top:1pt solid #000;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">Adjusted net income per diluted shares, excluding royalty revenue from Promacta</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">$</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">0.64&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr><tr><td colspan="3" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">GAAP - weighted average number of common shares - diluted</font></td><td colspan="3" style="background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="2" style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-left:1pt;padding-right:0%;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">21,277&#160;</font></td><td style="padding-top:2px;padding-bottom:2px;background-color:rgb(255,255,255, 0.0);text-align:right;vertical-align:bottom;padding-right:1pt;"><font style="font-size:10pt;font-weight:400;font-family:'Times New Roman',sans-serif;color:#000000;background-color:rgb(255,255,255, 0.0);">&#160;</font></td></tr><tr><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td><td colspan="3" style="height:15pt;background-color:rgb(255,255,255, 0.0);text-align:left;vertical-align:bottom;padding-left:1pt;padding-right:1pt;"></td></tr></table></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font><br></font></div><div style="text-align:center;"><font style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;"># # #</font></div><div style="position:relative;width:100%;height:45pt;"><div style="position:absolute;bottom:0;width:100%;"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>lgnd-20200506.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:68b0d68d-acb4-44fa-8fb0-389d70f74060,g:d3c0284d-4aea-42ef-aa86-73b1c056cdd7-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:lgnd="http://www.ligand.com/20200506" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.ligand.com/20200506">
  <xs:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20200506_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20200506_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20200506_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="lgnd-20200506_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.ligand.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>4
<FILENAME>lgnd-20200506_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:68b0d68d-acb4-44fa-8fb0-389d70f74060,g:d3c0284d-4aea-42ef-aa86-73b1c056cdd7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20200506.xsd#CoverPage"/>
  <link:calculationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>5
<FILENAME>lgnd-20200506_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:68b0d68d-acb4-44fa-8fb0-389d70f74060,g:d3c0284d-4aea-42ef-aa86-73b1c056cdd7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20200506.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended" id="ib65109477d22432aa4a952b61fc3a00a_CoverPage"/>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>lgnd-20200506_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:68b0d68d-acb4-44fa-8fb0-389d70f74060,g:d3c0284d-4aea-42ef-aa86-73b1c056cdd7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_WrittenCommunications_6cd75cad-6e74-496b-899d-2bc96ebb538c_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_870b44ec-67ac-4591-907e-664b608863a9_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_e08c4609-e9d7-4214-8a9f-dcbeec2a1ff9_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_bdb14f0a-7ba5-413f-b42d-ade9b2f63b66_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_82ba47e8-5c01-401a-a0fd-a93aeea1f44b_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_bdd54947-4e21-47f6-88e0-301a91b97562_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_2b554a9b-64cc-4d14-a560-56bc15c0928c_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_d318db58-65fd-459d-9874-024335ddf6e9_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0500c89b-67fd-4368-a063-19393e1f743e_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6a98b60e-04e1-46bd-ab74-2a1c71a6f1ed_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_57c12ae7-ca64-40e1-b7e7-f401e958202b_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_accaf00c-eea8-40b0-88b0-5c7391c3477f_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_044c2205-97aa-446c-86c2-f10a538290d8_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_29c986bf-33ee-43da-9b9d-c63c537c017a_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_53299c10-77a3-4ae2-a50d-f0664d6654bf_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_2f547ed8-eb8d-4016-a47c-ae9a1b1e5e8b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_d7c50365-a807-4f29-a70b-4770683cfead_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_cada2a54-0d48-4006-8301-7db3a2e0bb78_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_3301a0e3-f86b-483d-b587-271e12f5363e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_d316a3ff-163c-4bfc-88c3-0a2a611e3459_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_467884b2-de0d-419f-b09d-b471f0317d48_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ab0a18db-6b70-4925-aa7d-6d86dfef1797_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1ee9f7d0-9010-477e-88f9-64b1d4725ab1_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>lgnd-20200506_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2020 Workiva-->
<!--r:68b0d68d-acb4-44fa-8fb0-389d70f74060,g:d3c0284d-4aea-42ef-aa86-73b1c056cdd7-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.ligand.com/role/CoverPage" xlink:type="simple" xlink:href="lgnd-20200506.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.ligand.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_b1411945-757b-43b7-a6a3-a137252b5752" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityCentralIndexKey_b1411945-757b-43b7-a6a3-a137252b5752" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_601cccd5-2b0b-4478-b635-38252e08ee19" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_AmendmentFlag_601cccd5-2b0b-4478-b635-38252e08ee19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_7eb16afa-f596-48a6-a04b-4ba97c9ca9e4" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_DocumentType_7eb16afa-f596-48a6-a04b-4ba97c9ca9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_31168543-ee45-46c6-9d0c-933429915c47" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_DocumentPeriodEndDate_31168543-ee45-46c6-9d0c-933429915c47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e236a187-c341-4b29-84c8-65f5bf44fbde" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityRegistrantName_e236a187-c341-4b29-84c8-65f5bf44fbde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_b82ff418-f9fa-488f-affa-8a9fce6f5b6d" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityIncorporationStateCountryCode_b82ff418-f9fa-488f-affa-8a9fce6f5b6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d5731310-a688-4aab-84c7-fbd5dc0fcff9" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityFileNumber_d5731310-a688-4aab-84c7-fbd5dc0fcff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_c176fdcd-0814-42dc-8f21-23f004c387a7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityTaxIdentificationNumber_c176fdcd-0814-42dc-8f21-23f004c387a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_d59d6fbb-016f-476d-992c-ddbb14700bbe" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityAddressAddressLine1_d59d6fbb-016f-476d-992c-ddbb14700bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_7dd603e4-d473-400d-ac8a-6990ef7d603c" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityAddressCityOrTown_7dd603e4-d473-400d-ac8a-6990ef7d603c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f90504ac-1959-4e8c-802a-818e1207f437" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityAddressStateOrProvince_f90504ac-1959-4e8c-802a-818e1207f437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_f7a26afb-0858-4958-96e2-ad315fda13ce" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityAddressPostalZipCode_f7a26afb-0858-4958-96e2-ad315fda13ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ff6da41d-7993-4ea1-b459-dfd2476a4d63" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_CityAreaCode_ff6da41d-7993-4ea1-b459-dfd2476a4d63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_8f75ea64-7b14-43cc-b12d-b3475ee4eb48" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_LocalPhoneNumber_8f75ea64-7b14-43cc-b12d-b3475ee4eb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_a621021d-7440-4986-bbac-c9c6045ae5cf" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_WrittenCommunications_a621021d-7440-4986-bbac-c9c6045ae5cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_8596e140-c7a1-4634-a52c-1aeff958690e" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_SolicitingMaterial_8596e140-c7a1-4634-a52c-1aeff958690e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_b182a8e9-0269-4bb2-9123-9d86b8026c12" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_PreCommencementTenderOffer_b182a8e9-0269-4bb2-9123-9d86b8026c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_511ea13c-6c5f-4ddd-a381-36ab0a347c95" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_511ea13c-6c5f-4ddd-a381-36ab0a347c95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_244f05dc-f697-46a1-9d18-3d5b3da450ff" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_Security12bTitle_244f05dc-f697-46a1-9d18-3d5b3da450ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_9f50549b-f012-4d47-86d7-a62a7b4dbab0" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_TradingSymbol_9f50549b-f012-4d47-86d7-a62a7b4dbab0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_66531469-2499-4977-8383-b8d6637bb2b7" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_SecurityExchangeName_66531469-2499-4977-8383-b8d6637bb2b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_dfa304dc-97ed-41f5-8d18-3a15f1f92511" xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_bb572e75-2632-4aba-99b5-5587b48746b7" xlink:to="loc_dei_EntityEmergingGrowthCompany_dfa304dc-97ed-41f5-8d18-3a15f1f92511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>image11.jpg
<TEXT>
begin 644 image11.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0!817AI9@  34T *@    @ ! $Q  (
M   1    /E$0  $    ! 0   %$1  0    !   N(U$2  0    !   N(P
M  !!9&]B92!);6%G95)E861Y  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (+!<8# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%;-AXZ\/W_EK]M^SROGY+A2FW&>K?='3U_7B@#HZ*** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %?.-?1U?.- !1113 **
M** "O:_ 7_(EZ?\ ]M/_ $8U>*5[7X"_Y$O3_P#MI_Z,:@#HZ***0!1110 4
M444 %<9X@^'EAJ3/<:<RV-QM_P!6J#RF(![#[I/'(].A)KLZ* /&[KX=^(;>
M4)%;PW*E<[XIE !]/FVG/X=ZA_X0+Q+_ - W_P CQ_\ Q5>U44 >5Z3\,]0N
M'CDU.>.UBZM'&=\G7I_=&1GG)QQQ7HNDZ+8:):+;V,"H-H#R$#?(1GECW/)^
MF>,"K]% !1110!\XT444P"BBB@ HHHH ]'^%/_,7_P"V/_L]>CUYQ\*?^8O_
M -L?_9Z]'I %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 52O]7T_3%)O+N*
M(@!MA.6()QD*.3^5<;XM\6S?:)--TV1XA$^V:9258L#]U3U !ZGO].O$5Y.)
MS14Y.%-7\^A[&%RJ52*G4=D^G4]5F\;:%%$SI<O,PZ(D3 G_ +Z 'ZU4_P"%
MA:3_ ,^][_WPG_Q5>:T5PO-<0]K+Y'='*<.M[OYGJL/C;0I8E=[EX6/5'B8D
M?]\@C]:U+#5]/U-0;.[BE)!;8#A@ <9*GD?E7BU%:0S>JG[T4_P(GD])KW9-
M?B>[45P'A+Q;-]HCTW4I'E$K[89F)9@Q/W6/4@GH>WTZ=_7LX?$0KPYHGB8G
M#3P\^284445N<X4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !7SC7T=7SC0 4444P"BBB@ KVOP%_P B7I__ &T_]&-7BE>U^ O^
M1+T__MI_Z,:@#HZ***0!1110 4444 %%%% !1110 4444 %%%% 'SC1113 *
M*** "BBB@#T?X4_\Q?\ [8_^SUZ/7G'PI_YB_P#VQ_\ 9Z]'I %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !6=KM^=-T.\NU+!TCPA4 X8\*<'W(K1KE_'TTD7AU
M41L++.J.,=1@MC\U'Y5AB9N%&4EV-\-!5*T8OJSS&BBBOD#[,**** "BBB@
MKVO2[S^T-*M;LE"TL2LVP\!L<C\#D?A7BE>L^#?^13LO^VG_ *&U>ME$FJLH
M^7]?F>/G,4Z49=G^?_#&[1117T!\Z%%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5\XU]'5\XT %%%%, HHHH *]K\!?\B7I_P#V
MT_\ 1C5XI7M?@+_D2]/_ .VG_HQJ .CHHHI %%%% !1110 4444 %%%% !11
M10 4444 ?.-%%%, HHHH **** /1_A3_ ,Q?_MC_ .SUZ/7G'PI_YB__ &Q_
M]GKT>D 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *^<:^CJ^<: "BBBF 4444 %>U^ O^
M1+T__MI_Z,:O%*]K\!?\B7I__;3_ -&-0!T=%%%( HHHH **** "BBB@ HHH
MH **** "BBB@#YQHHHI@%%%% !1110!Z/\*?^8O_ -L?_9Z]'KSCX4_\Q?\
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M4Y# ]"#W%.H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHK-_X2'1?^@QI_\ X$I_C0!I45SG_">^
M&O\ H)?^0)/_ (FC_A/?#7_02_\ ($G_ ,30!T=%9<?B30Y8DD75[$*ZA@&G
M53@^H)R#[&KMK>6M]$9;2YAN(PVTM%(' /ID=^10!/1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 454NM5TZQ
ME$5W?VMO(5W!99E0D>N">G!JE=>*] LXA)+JUJREMN(G\TY^BY...M &Q17.
M?\)[X:_Z"7_D"3_XFG1^.?#<LJ1KJ:AG8*"T3J,GU)7 'N: .AHK-_X2'1?^
M@QI__@2G^-:5 !1110 4444 %%%% !7SC7T=7SC0 4444P"BBB@ KVOP%_R)
M>G_]M/\ T8U>*5[7X"_Y$O3_ /MI_P"C&H Z.BBBD 4444 %%%% !1110 44
M44 %%%% !1110!\XT444P"BBB@ HHHH ]'^%/_,7_P"V/_L]>CUYQ\*?^8O_
M -L?_9Z]'I %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!RNO>/=,T:62VB#7EVC;6CC.U4(QD,WKR>@/(P<5R<GQ0U<RN8K
M.Q6,L=JLKL0.P)W#)]\"N+N+B6[N9;B9MTLKEW; &6)R3@>]1TP.HN/B#XCF
MG:2.[C@4XQ''"I4<=MP)_6H_^$]\2_\ 02_\@1__ !-<W10!VO\ PL_6_P#G
MUT__ +]O_P#%ULZ;\4+>66./4K%H%*@--$^\;N,G;C(7J>I/UKS&B@#Z,CD2
M:))8G5XW4,K*<A@>A![BG5SG@+_D2]/_ .VG_HQJZ.D 4444 %%%% !1110
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MC?R+L8!MY6&XG&3M_O#@^_'(%(#?HHHH *^<:^CJ^<: "BBBF 4444 %>U^
MO^1+T_\ [:?^C&KQ2O:_ 7_(EZ?_ -M/_1C4 ='1112 **** "BBB@ HHHH
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MX\GU3S]/TT^58-\K2X(>4=_HI].I YZD5Q5%%, HHHH **** "BBB@ HHHH
M**** "BBB@ IT<CPRI+$[)(C!E93@J1T(/8TVB@#T?PI\0?]1IVLM_LK>LWY
M!_U^;/IGN:]%CD2:))8G5XW4,K*<A@>A![BOG.NO\&^,GT.5;*]9GTUVX/4P
M$]QZKZC\1SD% >OU\XU]#V=Y;W]I%=6LJRP2KN1UZ$?T/MVKYXH ****8!11
M10 5[7X"_P"1+T__ +:?^C&KQ2O:_ 7_ ")>G_\ ;3_T8U '1T444@"BBB@
MHHHH **** "BBB@ HHHH **** /G&BBBF 4444 %%%% 'H_PI_YB_P#VQ_\
M9Z]'KSCX4_\ ,7_[8_\ L]>CT@"BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH ^<:***8!1110 4444 >U^ O^1+T_P#[:?\
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M110 4444 >U^ O\ D2]/_P"VG_HQJZ.N<\!?\B7I_P#VT_\ 1C5T=( HHHH
M**** ,?Q7?OIOA?4+J+=Y@CV*5;:5+$*&!]1NS^%>$UZS\3KCR_#L$*S;6EN
M5S&&P74*Q/'< [?QQ7DU, HHHH **** '1QO-*D42,\CL%55&2Q/0 =S7O\
MI&FQ:/I-MI\)RL*8+<_,W5FP2<9))QVS7DWP_L?MOBV!RL;);(TS!QGH-HQ[
MAF4_A7LU( HHHH **** "BBB@ HHHH **** "J&N::-7T2\L"%+31D)N) #C
ME2<<X# &K]% 'SC16[XRM4L_%^I11EBK2"4[CSEU#G\,L:PJ8!1110 4444
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MKF? $B/X,LE1U9D:17 .2IWL<'T."#^(KIJ0!1110 4444 ?.-%%%, HHHH
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MBBB@ HHHH \#\0_\C+JO_7Y-_P"AFLVM+Q#_ ,C+JO\ U^3?^AFLVF 4444
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MTP"BBB@ HHHH ]9^&'_(M7/_ %^-_P"@)7:UQ7PP_P"1:N?^OQO_ $!*[6D
M4444 %%%% 'SC1113 **** "BBB@#VOP%_R)>G_]M/\ T8U='7.> O\ D2]/
M_P"VG_HQJZ.D 4444 %%%% !1110 4444 %%%% !1110 4444 <G\1K3[3X2
MDEW[?LTR2XQG=D[,>WW\_A7CM>U^/?\ D2]0_P"V?_HQ:\4I@%%%% !1110
M5]'5\XU]'4@"BBB@ HHHH XCXH2(/#]K$742-=!E7/) 1LD#T&1^8KRBO1_B
MM_S"/^VW_LE><4P"BBB@ HHHH *]_P!"C>'P_IL4J,DB6L2LK#!4A!D$=C7@
M%?1U( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OG&OHZOG&@
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MZI-?7#-EV.Q"V1&F>%'3@?3GD]34WB#Q!=^(M0-Q<'9&N1#"#E8U_J3W/?Z
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M&P#A@<@X/O7T57SC7T+I]W]OTRUO-FS[1"DNS.=NX XSWZT@+-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5\XU]'5\XT %%%%, HHHH *]K\!?
M\B7I_P#VT_\ 1C5XI7M?@+_D2]/_ .VG_HQJ .CHHHI %%%% !1110 4444
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M#\'W]:\DKVCP!(C^#+)4=69&D5P#DJ=['!]#@@_B* .FHHHI %%%% !1110
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M\XT444P"BBB@ HHHH ]'^%/_ #%_^V/_ +/7H]><?"G_ )B__;'_ -GKT>D
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M-P99E8XE8?PCU4'G/<@8Z9(!R6LW$5WKFH7$#;HI;F1T;!&5+$@X/M5*BBF
M4444 %%%% 'K/PP_Y%JY_P"OQO\ T!*[6N*^&'_(M7/_ %^-_P"@)7:T@"BB
MB@ HHHH ^<:***8!1110 4444 >U^ O^1+T__MI_Z,:NCKG/ 7_(EZ?_ -M/
M_1C5T=( HHHH **** "BBB@ HHHH **** "BBB@ HHHH YSQ[_R)>H?]L_\
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MBUXI7M?CW_D2]0_[9_\ HQ:\4I@%%%% !1110 5]'5\XU]'4@"BBB@ HHHH
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M%% !1110 4444 %%%% !7M?@+_D2]/\ ^VG_ *,:O%*]K\!?\B7I_P#VT_\
M1C4 ='1112 **** "BBB@ HHHH **** "BBB@ HHHH ^<:***8!1110 4444
M :6DZ]J>A^=_9USY/G;?,_=JV<9Q]X'U-:7_  GOB7_H)?\ D"/_ .)KFZ*
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M7!FF(RL:_P!2>P[_ $!([;QUI-IHO@JSLK*/9$MXI)/+.VQ\LQ[D_P#UN@H
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M -_'_P#B*ANOAOK]O$'B%K<L6QLBEP0/7Y@HQ^/>@#D**Z3_ (0+Q+_T#?\
MR/'_ /%4?\(%XE_Z!O\ Y'C_ /BJ .;HK6N/"^NVT[0R:3>%EQDQQ&1>F>&7
M(/YUDT %%%% !1110 4444 %:WA_Q!=^'=0%Q;G?&V!-"3A9%_H1V/;Z$@Y-
M% 'T'IFI6^KZ;!?VI8PS+E=PP00<$'W!!%6Z\B^'WB!M,U8:=,<VMZX49)^2
M3HI 'J< _@<\5Z[2 **** .%^(/A?[=;'5[-(UN+="UP.AD0#KGIE0#[D=^
M*\KKZ.KR_P ;>"?L?F:KI47^C<M/;J/]5ZLH_N^H[?3H <#1113 **** "BB
MB@ HHHH **** "BBB@ HHHH **** "I[.SN+^[BM;6)I9Y6VHB]2?Z#W[5;T
M;0M0UZY,%A#OV8,DC'"Q@G&2?Z#)X. <5[#X?\+Z?X=@'V=-]TR!9;AOO/SG
M@?PC/8>@SG&: ,>V\*V_ASP?JK-MEOY;*7SI@. -A^5?1?Y]3V \DKWSQ#_R
M+6J_]><W_H!KP.@ HHHH **** /6?AA_R+5S_P!?C?\ H"5VM<5\,/\ D6KG
M_K\;_P! 2NUI %%%% !1110!\XT444P"BBB@ HHHH ]K\!?\B7I__;3_ -&-
M71USG@+_ )$O3_\ MI_Z,:NCI %%%% !1110 4444 %%%% !1110 4444 %%
M%% '.>/?^1+U#_MG_P"C%KQ2O:_'O_(EZA_VS_\ 1BUXI3 **** "BBB@ KZ
M.KYQKZ.I %%%% !1110 4444 %%%% 'DGCGPF^E7<FI64*C3I6&Y8Q@0,>Q'
M]TGH>@SCCC/&5]&21I-$\4J*\;J596&0P/4$=Q7DGB[P3/I$[7>G123:>V6*
MJ"S08&2#_LX_B_ ^I8''4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !70^%?"MQXCN]S;HK")OWTP')/]U?5OY=3V!V?"_P^GOMEYJZR6]NK\6S*
M5>0#KGNHSCW(STX->I1QI#$D42*D:*%55& H'0 =A0!!8Z?::9;+;V5O'!$/
MX4&,G &2>YP!R>:Y/XG_ /(M6W_7XO\ Z ]=K7%?$_\ Y%JV_P"OQ?\ T!Z0
M'DU%%%, HHHH *]K\!?\B7I__;3_ -&-7BE>U^ O^1+T_P#[:?\ HQJ .CHH
MHI %%%% !1110 4444 %%%% !1110 4444 >!Z]I,NBZS<V4D<B(KDPF3!+Q
MY.ULC@Y'ZY':LVO<?$?A6P\1Q*9]T-S&I$<\8&0.>&'=<\X_(C)KR_4O!&OZ
M:QS9-<Q[@HDM?W@)(ST'S =LD#^5,#GJ*TO^$>UO_H#ZA_X#/_A1_P (]K?_
M $!]0_\  9_\* ,VBM+_ (1[6_\ H#ZA_P" S_X4?\(]K?\ T!]0_P# 9_\
M"@#-HK2_X1[6_P#H#ZA_X#/_ (4?\(]K?_0'U#_P&?\ PH S:*TO^$>UO_H#
MZA_X#/\ X4?\(]K?_0'U#_P&?_"@#-HK2_X1[6_^@/J'_@,_^%'_  CVM_\
M0'U#_P !G_PH S:*TO\ A'M;_P"@/J'_ (#/_A1_PCVM_P#0'U#_ ,!G_P *
M ,VBM+_A'M;_ .@/J'_@,_\ A1_PCVM_] ?4/_ 9_P#"@#-HK2_X1[6_^@/J
M'_@,_P#A1_PCVM_] ?4/_ 9_\* ,VBM+_A'M;_Z ^H?^ S_X4?\ "/:W_P!
M?4/_  &?_"@#-HK2_P"$>UO_ * ^H?\ @,_^%'_"/:W_ - ?4/\ P&?_  H
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MZQ (=0M(YU'W2PPR\@\,.1T'0\T ?/U%>@:M\,+B-FDTFZ66,*3Y5P=KY '
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MNCK-T#2_[&T*TT\MN:)/G.<@L26;' XR3CVK2I %%%% !1110 4444 %%%%
M!1110 4444 %%%% '.>/?^1+U#_MG_Z,6O%*]Z\1Z4^M:!=Z?%(L<DJC:S#(
MR&# 'V.,9_G7BNI:'J>D,1?V,T*A@N\KE"2,X##@G'H>QI@9]%%% !1110 5
M]'5X[X3\'ZAJ6H6MY<6WE:>CK(S3IQ*!@[0IZA@>O3&>O2O8J0!1110 4444
M %%%% !1110 4444 >?^)?AREPSW>B%8Y68L]LYPAXZ)QP<]CQSU &*\UN+>
M>TG:&XADAE7&Z.12K#(SR#[5]%5FZSH6GZ];""_AW[,F.13AHR1C(/\ 0Y'
MR#B@#P.BNZU;X9ZA;O))ID\=U%U6.0[).O3^Z<#'.1GGBN,NK.ZL91%=VTUO
M(5W!98RA(]<'MP:8$%%%% !1110 4444 %%%% !16IIOAS6-64/9:?-)&5+"
M0C8A .#AFP"<]L^OI7>:+\,[:#$NL3_:7_YXPDJ@Z]6X8]CQC!'>@#S_ $G1
M;_6[M;>Q@9SN >0@[(P<\L>PX/UQQDUZIX:\#V&B*EQ<A;J_V@EW *1L#GY
M1P>G)YXXQDBNFM[>"T@6&WACAB7.V.-0JC)SP![U)2 **** "N*^)_\ R+5M
M_P!?B_\ H#UVM8_B?0QX@T26R#*DP820NV<*X]<=B"1WQG.#B@#PFBK=_I=_
MI<OEWUI-;L6*J9$(#$==IZ$=.1ZU4I@%%%% !7M?@+_D2]/_ .VG_HQJ\ATW
M2-0UB<PZ?:23L/O%1A5X)Y8\#H>IYKV_0-+_ +&T*TT\MN:)/G.<@L26;' X
MR3CVH TJ***0!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !5:[T^RO]GVRSM[C9G9YT2OMSUQD<=!5FB@#-_X1[1?^@/I__@,G^%'_
M  CVB_\ 0'T__P !D_PK2HH I6^C:7:3K-;Z;9PRKG;)' JL,C'! ]*NT44
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M+2A9!CTP O/3G-=Y10!YI<?"N=8&-OJT<DO&U9("BGGN03CCVJC_ ,*PUO\
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M444 4)-"TB:5Y9=*L7D=BS,UNA+$]23CDTS_ (1[1?\ H#Z?_P" R?X5I44
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M*L4D1@RLMN@*D="#C@U?HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .#^*5TB:
M18VA#>9+.95..,*I!S[_ #C]:\MKT#XIW2/?:=: -YD4;RL<<88@#'O\A_2O
M/Z8!1110 4444 =9\.;3[3XMCEW[?LT+RXQG=D;,>WW\_A7L5>6_"V!&U>^G
M,RB1( BQ=V#,"6'/0;0/^!#\?4J0!1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %><?%;_F$?]MO_9*]'KROXGWWG:S:62M&RV\)<[3E@SGD'\%4
M_C[T <+1113 **** "ND\!?\CII__;3_ -%M7-UU7P[M7N/%\$J%0MO')*^3
MR05V<>^7'ZT >R4444@"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@#R;XG_\ (RVW_7FO_H;UQ5>C_%;_ )A'_;;_ -DKSBF 4444 %%%% '8
M_#2XBA\4O'(V&FMG2,8/+95L?DI/X5Z[7SUI]]/IFH07MNV)87#KR<'V..Q'
M!]C7OFGWT&IZ?!>V[9BF0.O(R/8X[@\'W%("S1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 -DD2&)Y975(T4LS,<!0.I)["O ]<U(ZOK=Y?DL5FD
M)3< "$'"@XXR% %=S\0/%B>4^BZ?,WF;L74B'@#O'GN?7'ICG) \VI@%%%%
M!1110 5Z/\++#_D(:B\7]V".3=_P)QC/^YSCZ=Z\XKW/PEIG]D^&;*W9-LK)
MYLN8]C;FYPP]0"%Y_N_A0!MT444@"BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5YU\
M2O#Y=4URW1<(HCNN0#C("MTY/.#S_=XP#7HM-DC2:)XI45XW4JRL,A@>H([B
M@#YSHKK_ !EX-?0Y6O;)6?37;D=3 3V/JOH?P/.">0I@%%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH5548"@= !V%.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
>HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.20.1</span><table class="report" border="0" cellspacing="2" id="idp6615031312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 06, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000886163<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  06,  2020<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIGAND PHARMACEUTICALS INC<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">77-0160744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3911 Sorrento Valley Boulevard, Suite 110<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">550-7500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LGND<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>11
<FILENAME>0000886163-20-000056-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000886163-20-000056-xbrl.zip
M4$L#!!0    ( &: IE 1/(I^1!4  )V<   1    ;&=N9"TR,#(P,#4P-BYH
M=&WM/6M7XLBVW^=7U&7N/<=>RX*\']CM6;;0#&=,Z!;4@2^N2JH"T9 P25#P
MU]]=24!04>QI6[!UK9DVII[[_:K*Q_],A@&Z8G'B1^&GDE@62N@_^Q__!^._
M/A\?H5KDCH<L3-%AS$C**+KVTP$ZHRRY1%X<#=%9%%_Z5P3CK,]A-)K&?G^0
M(DF0A#LOXZIF. +5#(J)ZRA843R"#<\1L&R85!<\71$T8;=?I;(K2(9"L4(8
MP8K$/$R(H6%==D174#674GV75@TF:(KN*<S5%<6 '\&5B.X:*J4.<T2%3SM(
M87>PPS"I!GYX^:DT2--1M5*YOKXN3YPX*$=QOR()@ESAKQV2L%+1W)^D.&'N
M4@]X+O>CJXH?0FO& 51)8Q(F7A0/20H A*%$%0L&EL5BG*7^UW(VGVB:9F7"
MEW8[V:J5B?+";+/FE/GS]EG;V<+@!>]C8D&\74*5-_$?V;H?)BD)W?G6)_=
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ML$(9P8Z@.U@P1,-33")170 CF@7D&HS5^T'_0F(6K/>Z3)4/^<Y4#YEP7_R
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M&R)E7H:.LP[RO0[X_EWEFR245@3,OBYYHS1S!!8<[(?4Q^-9QT<O;W^&%?Z
M1?]"'5]V.0]_0/F[79 G.FY,P/"U@G]/J997=>>>_'IW<0ZEV; /.B?']?9:
M1P!E;5FE/NP 2\(F"Z-\XXN?:<_S/'^/_;CP8I\?3ME]*%E$Q\$4N63,$SP+
M,34^I0/.(  07O#@$4SIL $)/!Z<X -EZK)HP"-U8WX!>S8<>(>#*(:=TM4>
MZ+*Z,>Z)Q@WR24VU;!8G5I[_,0J@&/U%7%(55B7_()?T%[@-<2W/:TMNDEW]
MK>U[W]9>!_LSH9.5!6X4)6S"RC;)$?W1Q/HS*C5K8$-7%VWHURJ]_6&QEZ5"
M0EG.BP:7O2'C(=P4"%NP@#<[;K/"1?H\K:*7*MKX:4&)2E+AE^/% 4S7+J//
M++Z$^=#L9[V[)GX]W/-Z9X[]!V#W#K*'09:=MLI@UF:A'\7HU'<9XG$&GX-D
M=Y[,Y=]Q3UB0I:? JH]92N(I^B<!AX6<U3-N$<S\I^WWN"M.1*?PSR =!OO_
M#U!+ P04    " !F@*90FXGPGJ0"   +"@  $0   &QG;F0M,C R,# U,#8N
M>'-DW59;;]L@%'[/KV!^'C%.TMS4I-):59J4792U:M\F#,<.J@T>X";]]\,D
M7F[-,D][V"99,CZ<[^-\AW/ EU>K/$//H(U0<A)$;1(@D$QQ(=-)<']WBX?!
MU;35NGR#\>.[^0S=*%;F("VZUD M<+04=H$>.)@GE&B5HP>EG\0SQ7CJ0=>J
M>-$B75C4(1UR.*O'_6%,>'_(,65Q#_=Z"<7#)":X.QSQ 4D&/=(G;],Q[S+2
M&?8X[E&@N->!!%,Z[.-!-XX8N>@SS@>>=&7&ABT@I\@)DV:\,I-@86TQ#L/E
M<ME>=MM*IV&'D"A\_##[XEV#C6\FY-.>]RK66>W?#:OIF!KXX9Y*ON>>B91*
MWF8J#RNQY(+T T2MU2(N+=PJG=] 0LO,3H)2?BMI)A(!W"4\@RJE>PX[TY;J
M%.Q'FH,I*(.S2TY;"%5Y$'FAM$7R")A0$WM9I<$II86#1B-,(MR- K3.WDPQ
M:GU);# ^%:\"0\BLJ2UX2]5>&1Z$9X/9V95H-!J%JRK-)\,XWA7OCZLACCK-
MEMTG$M)8*ADT6=M]X1KW)V+8EEBS&&I<\Q@\F0'63M5SR$&<K05S"E0-3FX_
ME5)9SU)9-K:B$#)1:X,S52+&M9(Y)'4''[7E*^7B7V.JF5;9F=H*"ZT*T%:
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M$22_OB3C%W5&%;M3\["[D_U8(HC]3R-B\D)SP8/"&K]Z[<WB#U!+ P04
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MP/<8"U@:>EGDYMQGE+*_%T13<C&6YZ-_4$L#!!0    ( &: IE"J&+^:APH
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M5!6N&O\U-;@VP,8*7#_:/0E<Y]P^8^_KXTQD4[N7F? @C@$B@018Q!(P)@,
M354F".D AZWW,E<LGYK4E^"\!;KVRJ[2M5_,G4DX]AI6N_B=Y%H;:P^%5NT-
M)LK:,-9U6#^@]Q. /LSG=SI??UX-)I0Q+'R@-%0 HR@& D:F%&.*8A@@:B;)
M'9\#M.7LU 2Z]9";!>+#/!1HF^K]2CXD@4<6=R_N^CPGJ)&4PSTM:-O%KWIF
M4&.P.YX<U/R=[KN[GA[[^(?IR<=<0&[O1P)$4 APY(> <ZH 48RH6,>(1M1U
MFU?%PZDEBJ<M3PN4GH'I69SN6[^J1.[/"+WI.7(:<&:FT[ZPVN@/L$&L:G?P
MG6*U8=5M&:L?V+4;_Z(GB;UC(RW*.UJ1UE%,%0011-"NAVLS'X\C0+! "E,_
MY *Y]>%5!Z<FYF5;^0S2\;;@6A+;MMS=J1FFV6[+2H<>NS[TWMWUAMF!^^KZ
MH+8[ZH9Q31)>Y_W*'%V\6+V3+!Z ?O'B_U!+ P04    " !F@*90!6!?OK(&
M  !N,0  %0   &QG;F0M,C R,# U,#9?<')E+GAM;-6:6T_<6!+'W_D4O3VO
M>^ASOZ# B&62%1IF@A)&&>U+ZUR[K;CMUK$)\.VW;&"2#F36HBWA?6FZ[6-7
MG7_]5%4N_.;GVTTY^Q)S4]35\9P<XODL5KX.1;4ZGO]Q]0[I^<\G!P=O_H'0
MG__Z<#'[I?;7FUBUL[,<;1O#[*9HU[-/(3:?9RG7F]FG.G\NOEB$3OJ+SNKM
M72Y6ZW9&,<7?G\U'4CL<I [(>L<1Y\DBG1Q&3)N@<%(<2_S/U5%@'E/- ^(V
M6L1I3,A:+9%BCG@LI ]!]3<MB^KS4??A;!-GL+FJZ7\>S]=MNSU:+&YN;@YO
M72X/Z[Q:4(S9XG'U_&'Y[9/U-ZQ?38PQB_[L7TN;XKF%<%NR^/.WBX]^'3<6
M%573VLIW!IKBJ.D/7M3>MKWF_].OV0]7=+_0XS+4'4*$(D8.;YLP/SF8S>[E
MR'49/\0TZ_[^\>%\QV19K&P5#GV]672G%V<UP'!I5YVS_<7MW38>SYMBLRW_
M.K;.,1W/RU454!=5++#L3/[T]>+%5^O;'!L IM_M!1QXN$=G[26>Q-LV5B'>
M[^_11EG[G45EIVZ='Z\LK8ME?W098K'L[WSJFC9;WRZ=$XI&)1"5C )?SB)C
MG$!":.6X5EPZM;OQSND&O.Z#T41_N*J_+.#&$!1BNB^H^X(P>0C%3T^,WNOS
M,N_?5FW1WIV!I-F6YR#%[:_Q;ND()\1P@910#G'F%++2,F0)4U10V*.@(^SB
M6>.[N_DVWJ?9S^H<8H;4\FC=9O\D]KM8/ZQ8;&V&&R&_+LKP>'678\:(9%N/
MJ>A]W,#O^0RVGV+.,5S<A^V'N^RWV$+FC?W*?9 XA8P<NJS\KK2KI<3$>Q]
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M/:I\UH5A>$Q^5KF_O*-1\F;Q1,H+.'!R\'"B^^A>T#\Y^"]02P,$%     @
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M =U.Y?#B@YC'29:R7X,DS=B_<I[ V&5\Q:]!Q",OX"%<E.9AEJX),]C!A?G
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M20##- BP@L")XI( $XP)@\L '<3C,3X1\55A,J" SSW"4O#4= X  62VE\1
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M1^1'J*+/9=#ID$/8"T6<$;G"EL:3'&]*<WE@=P?F0\U:N"%^C6.?-OHHR2=
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M1 8+D'X1MN+&'33;=?=EB9;ACA\/W'J[^Q+7'R0MGCJ!0@5=*5;W+H+W@"9
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MQ4Q\6N(+B:#H?%95 9S-,%:,# 'VA]OI][M=ITB-D([%5(2JF\"89]B>R@M
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M94A1@I&S!Q=$)4[\%M]@FH6C8I6H]XX*5Z>Z$[ADRTU@'7JFYHTX"JEJ^W6
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M PR=<ER6]R[SM$HK7'</*2(H9+Q0416G<@J[4B&_K)*H<U3*5VT%:6T%;04
M\#Q].$BG17K9L2 ;9<9+[S[FH0+PV+"/<F=6"(HDU5@^&@-(\6CH6I\05NZN
M1':I'+MH2D=,Y*:2C[Z9RC+$*Z\H6MK0??KL%FSB.$\\TE>PV#?9M'HT5_7G
M8# 6&P.V6D?%F">PD$5&L(BGKG11IMN3$5O4Y2D?@99W5.1$JF1+,BF2E9RO
M2NQ8D2!0S3706?&E4E^_\LMOU4X@&:$DJK?#"&[?C5\41^2%D)#'BWD8UA:"
MJVJ=Y6FC2EFT8O[16''H93G5MY1GITF1%8J%_M!FQ&+:>-)4P#2I\E6 @@HW
MV(3SBA"$(+K%I\I4K 0.K%,E5:5!8\)P"5W?I<A:U8Y?&FE1RL4I=0E5<W$(
MRB8@>JHFN;ZYI.G;TF@J2^@D^1S?MJK";C$'?;%NAIAQPQ>WZMM2K8K:O7A2
M^@M4!5PY*7H_2%3IT5>!]1B<$>/0.98+ @V[4C%/AF2@WQ.?&RY41 T**?2$
M2@F].E--&_"4,FI6%>_3+(K5* .U<X5TOJV"]5:.0'"JJCUXQHKE^Y**BP,'
M)AL846R&FOE!^E)+\T":\V%%0*)D5Q)Z:0SZE:JD*=U>"""$"RALY!TKJ$ O
MN(?%B7UR19;";=V4R@F453,EX<H%I&+RLAR?S,U:HE,YADJ%SQD=8#,$+0DU
M9:9V/^I=,NY$'>!B)N/Z/-N"J&E#V[TWZJ)?CX;T?"R6DJI#X.OXDUP>4=2&
MIFIPU=K0JX7)[WYIM2W54KW;:IE;52$*2P[JD16Q'OHP9VD(4<Q"3!-.J,:B
M*J"/=6C)^^]A029L)XI#PWK7N-%K*:)"A/*P2FMM'? E65&K;=K]RHE:$&$;
M>IG:6LF[UMM8\ Q2\!*3+ZHCD.3OL#&_CA,:CNIM$R0S>7"E]E]*!_ET19DZ
M?+%*MQO5[RTQ6CDQT;U*"V%(U8?+5=)A6$65A)(A<:EPZY:85PU('6+)IPM?
M/EWY](9>(L^MWNJ#3'3L39:+".(<X@H6*R;C%,,3GX6'P:,R]#!(5 4ON<^Z
M3:PL9U:VCA5^N83XJ12.%2<H'A9J44JR1AZ1E32T:7$K-*6.5]2P\"DA>CYR
M>7()@E2=D,C3&(Q5NI8P3X?C%4,D!TOUR%9)!NV2%G(\$>P@R2F_.M2?5D:I
M3TZD:%4A=96*C_$R/4D8N7R IJE:W:S'N9;)BL.U5:VMB9<$CBZ1>JN27EH(
M4KP_(<?N4@ 8A=LR505?<MURA7?2O=67*8-S%4S?I;(J[U:/4\=VM#0J%,BI
M5%5PEK!WHHI]!:EL-JQUNY"3'FMBNJ5O9#AT9;94OS]=P<W<%W_FJLP.1?0O
M5U>11PZTL12P2 Q330!8QAK+I;/5BE8TEZ^7G$(!<#%HE(3=2I*K&/CQB*AY
MH[C)HX(T%!)A%-Q41%8B:<LY9DNB=JF^4$GLI6R24Z!!$E @RLO6C60MF7])
M:2R)O* H[DTT1EG>$QBCL@E1 JG3:(Q[S84Z#5H"'(H(BFPC;:F6EA.HO5A%
M<RA=A7&SLM:\FBXL)B94:;]LO$0_E5!;U07G6HIW"0B+#9!KK^.YB] ":W\]
M8I+%F <A[J"N%;UD8:U&HBMQ2V9RC)T_I36!!S.I G) ]:)D PJV 0H*/.LZ
M?T2[N:R65SDX9-3--8F40%8!YA*X4.P.FGP4-"1!>U&="D4]2I0QE3DGE1](
M056F*MP9A(F*[T9@C&5:&MLH!&5,/.71^-B**@@IVKLXDKW$\J2E'#C^+./N
M,8![%I K_O9K4^'5)_&U):?'CO&C7#H>8,Q!M)"''P2\XE&H93M&+,G.>-F7
M//0CL8A5T?QU!VE5OX3T0:9%EB 59BHHO'";:#_+C5"BA@P(2P>/>_KJ<0G+
M@E0FS.1%N60R[Z?8@3>1?N>TVG#F(@FN<9\K+'U:@H(/%)P'YA8A#'<PZ-A^
MISL5([4A:N&<M,^1DBPBD7+^"DNTH V\6[$+2V$\TC9;S?BKV$S:OLXJM9F7
M;.TR][\4E?]<S+%R #E>I0]#W^.PXS_.WQ^?#N57M_P:Y77X[/_W\?3#\>7E
M.699W/9W%)=B#IKJ5%6=FM3KX4+/JDB\BF_(6-69@VNGL]111/DE98YXJ))O
MM?LCBF4%ZB!RUMDIRZ^00DF^8=="@N[6V[#H-'U<LK*D35;PF#+XY@O]I6IY
MEZ=%#F2DDO$+8%9XV+5!6 37E;2XG+8?\1DH]3">Q/*%*HT?MEO*@,WC >M7
M\$3Z,M>Q#(9B*'>?=%=)C1,DVC(A]S-1G@KJK;RKND8ZM5I^]JP-EZG*PA>W
MV/3^RG>39WD"MMU+S;9@K9'&96K =J_U%BQUG5V"4@IE,CK(3C!*R"?KR/:
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MN7PTJ=VVZ,6B%\L']99%+Q:]["-Z,8>FECJG)R+D>$R>Q8R7W;I2W:Z+1Y,
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MWK#;)B\:]?[ +&'QY:7==C%B>6<W>*?E&M<D9/>9QTQM::US VGJ'0\B=8S
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MSS2;A;_\?U!+ 0(4 Q0    ( &: IE 1/(I^1!4  )V<   1
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M,#(P96%R;FEN9W-R96QE87-E92YH=&U02P4&      < !P#2 0  J'P

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M^L/O)NR"L0?[CXVO@K*%7W<AOP!02P,$%     @ 9H"F4)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M<FEN9W,N>&ULA51M;YLP$/[<_8I3M ^;E)27-"^=TDB,I!EJFK*2;=*F?7#
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M   +              "  0    !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( &:
MIE GZ(<.@@   +$    0              "  >D   !D;V-0<F]P<R]A<' N
M>&UL4$L! A0#%     @ 9H"F4(7(/3#O    *P(  !$              ( !
MF0$  &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 9H"F4)E<G",0!@
MG"<  !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"
M% ,4    " !F@*90VKT5X)T"  "3"P  &               @ 'X"   >&PO
M=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 9H"F4%,G.CAP @
M!08  !0              ( !RPL  'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!
M A0#%     @ 9H"F4+JA.8K7 0  ,@8   T              ( !;0X  'AL
M+W-T>6QE<RYX;6Q02P$"% ,4    " !F@*90+6VE:#H!   G @  #P
M        @ %O$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ 9H"F4/_
M)@B]    A0(  !H              ( !UA$  'AL+U]R96QS+W=O<FMB;V]K
M+GAM;"YR96QS4$L! A0#%     @ 9H"F4 N/V ,A 0  5P0  !,
M     ( !RQ(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      H "@"  @
&'10

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "lgnd-20200506.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "calculationLink": {
     "local": [
      "lgnd-20200506_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lgnd-20200506_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-eedm-def-2019-01-31.xml",
      "http://xbrl.fasb.org/srt/2019/elts/srt-eedm1-def-2019-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "lgnd-20200506.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lgnd-20200506_lab.xml"
     ],
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lgnd-20200506_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lgnd-20200506.xsd"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd",
      "http://xbrl.fasb.org/srt/2019/elts/srt-roles-2019-01-31.xsd",
      "https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd",
      "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 23,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2019-01-31": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 95,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "lgnd",
   "nsuri": "http://www.ligand.com/20200506",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20200506.htm",
      "contextRef": "ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.ligand.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "lgnd-20200506.htm",
      "contextRef": "ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications",
        "terseLabel": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.ligand.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 0
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r6": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>lgnd-20200506_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="lgnd-20200506.xsd" xlink:type="simple"/>
    <context id="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000886163</identifier>
        </entity>
        <period>
            <startDate>2020-05-06</startDate>
            <endDate>2020-05-06</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF80L2ZyYWc6MzExNDFmZDU5MWY1NDQ2NmEyYWM3ODYzMTRiM2Y3NjEvdGFibGU6ZjczMWZhNDRmNzRiNDk2NTg4MTg5OGVlODE0NTA4M2UvdGFibGVyYW5nZTpmNzMxZmE0NGY3NGI0OTY1ODgxODk4ZWU4MTQ1MDgzZV8yLTEtMS0xLTA_7df9b12c-7d3b-44f6-9502-4772b81fb58e">0000886163</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF80L2ZyYWc6MzExNDFmZDU5MWY1NDQ2NmEyYWM3ODYzMTRiM2Y3NjEvdGFibGU6ZjczMWZhNDRmNzRiNDk2NTg4MTg5OGVlODE0NTA4M2UvdGFibGVyYW5nZTpmNzMxZmE0NGY3NGI0OTY1ODgxODk4ZWU4MTQ1MDgzZV8zLTEtMS0xLTA_649ca818-bc64-410f-b168-55bed80d4d84">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV85Nw_7640994b-b3f2-48a2-963e-64b87c25278d">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8yNTI_8d4d1570-b7f5-4e47-bc6d-4007a1dec0f2">2020-05-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8yNTY_994597b9-893c-4867-b162-60d626854bad">LIGAND PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6MmRiNDk2Y2VjMWM0NDNlYWIwZDhhODMxNzQ0NGZkMDYvdGFibGVyYW5nZToyZGI0OTZjZWMxYzQ0M2VhYjBkOGE4MzE3NDQ0ZmQwNl8wLTAtMS0xLTA_57e4f534-e176-4dea-b07b-0818f49a2d70">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6MmRiNDk2Y2VjMWM0NDNlYWIwZDhhODMxNzQ0NGZkMDYvdGFibGVyYW5nZToyZGI0OTZjZWMxYzQ0M2VhYjBkOGE4MzE3NDQ0ZmQwNl8wLTEtMS0xLTA_f3990a00-5638-4bcc-9a6a-a9d3b5fdf5d4">001-33093</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6MmRiNDk2Y2VjMWM0NDNlYWIwZDhhODMxNzQ0NGZkMDYvdGFibGVyYW5nZToyZGI0OTZjZWMxYzQ0M2VhYjBkOGE4MzE3NDQ0ZmQwNl8wLTItMS0xLTA_9f00277d-0a79-4f57-9f73-f044e3bd14f1">77-0160744</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8wLTAtMS0xLTA_133912ed-e2e6-44f9-aa55-d520acea1de6">3911 Sorrento Valley Boulevard, Suite 110</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8xLTAtMS0xLTA_b67a6e6a-2c07-4bbf-86e8-85bbacf46776">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8yLTAtMS0xLTA_56779583-f645-43be-b9b0-5572cbb990c7">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2M3Njc3YzM1NzU4NDg1YzhmNWE1MzIyYjM5ZWMxMDkvdGFibGVyYW5nZTo3Yzc2NzdjMzU3NTg0ODVjOGY1YTUzMjJiMzllYzEwOV8yLTItMS0xLTA_3bddcea9-9306-4eea-9649-249c4301bfcd">92121</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8zMzQ_66d57574-1677-4881-a987-1616dc6b531c">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8zMzg_0156b96d-bd43-4845-a696-f535e8f77927">550-7500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV82MzU_a0e562e0-816f-459f-9cbb-8ee09fcf2a25">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV83MjQ_404c6f2a-c053-4751-8b38-5b56adc7b922">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV84MTQ_7cb8f7cc-af9e-49dd-b12d-28915b387667">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV85MjA_48384577-b3a8-4465-b415-f3eb0ea56eda">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2I3MTRhYTc3ZDNjNDE2NDlkZWE3YzE5NThmMTg3N2IvdGFibGVyYW5nZTo3YjcxNGFhNzdkM2M0MTY0OWRlYTdjMTk1OGYxODc3Yl8xLTAtMS0xLTA_bb6cecbf-0423-48b8-87be-fb2f6209d5bb">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2I3MTRhYTc3ZDNjNDE2NDlkZWE3YzE5NThmMTg3N2IvdGFibGVyYW5nZTo3YjcxNGFhNzdkM2M0MTY0OWRlYTdjMTk1OGYxODc3Yl8xLTEtMS0xLTA_39bf7059-858c-4532-905f-1bb86cd75b66">LGND</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGFibGU6N2I3MTRhYTc3ZDNjNDE2NDlkZWE3YzE5NThmMTg3N2IvdGFibGVyYW5nZTo3YjcxNGFhNzdkM2M0MTY0OWRlYTdjMTk1OGYxODc3Yl8xLTItMS0xLTA_1438e758-265a-477f-8782-bb8b5f0dbd66">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib442500fbd1a4d24807da6dbc88f8e17_D20200506-20200506"
      id="id3VybDovL2RvY3MudjEvZG9jOjhlMDY0N2Y0ZWM3NDQ4ODg4MGMyYTdjODVkZGJlYjE0L3NlYzo4ZTA2NDdmNGVjNzQ0ODg4ODBjMmE3Yzg1ZGRiZWIxNF8xL2ZyYWc6OWNkOTM0ODk0OTMyNDdkMThmYmVhZmNiZWZkMGU1MTUvdGV4dHJlZ2lvbjo5Y2Q5MzQ4OTQ5MzI0N2QxOGZiZWFmY2JlZmQwZTUxNV8xMzU0_766ad7f2-584f-4ba2-a079-1756ff76b9c6">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.20.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>95</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="lgnd-20200506.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.ligand.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="lgnd-20200506.htm">lgnd-20200506.htm</File>
    <File>lgnd-20200506.xsd</File>
    <File>lgnd-20200506_cal.xml</File>
    <File>lgnd-20200506_def.xml</File>
    <File>lgnd-20200506_lab.xml</File>
    <File>lgnd-20200506_pre.xml</File>
    <File>q12020earningsreleasee.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
